# reload+after+2024-01-22 16:44:05.349030
address1§6550 South Millrock Drive
address2§Suite G50
city§Salt Lake City
state§UT
zip§84121
country§United States
phone§801 676 9695
website§https://clene.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
fullTimeEmployees§75
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert  Etherington MBA', 'age': 56, 'title': 'CEO, President & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 590982, 'exercisedValue': 0, 'unexercisedValue': 1130337}, {'maxAge': 1, 'name': 'Mr. Morgan R. Brown CPA, M.B.A.', 'age': 55, 'title': 'Chief Financial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 374046, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark G. Mortenson ESQ.', 'age': 65, 'title': 'Chief Science Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 482977, 'exercisedValue': 0, 'unexercisedValue': 584464}, {'maxAge': 1, 'name': 'Mr. Jerry  Miraglia J.D.', 'title': 'General Counsel & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael T. Hotchkin', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mary Anne Mcneil', 'title': 'Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Benjamin M. Greenberg M.D., M.H.S.', 'title': 'Head of Medical', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.512
priceToSalesTrailing12Months§51.867188
currency§USD
dateShortInterest§1702598400
forwardEps§-0.32
exchange§NCM
quoteType§EQUITY
shortName§Clene Inc.
longName§Clene Inc.
firstTradeDateEpochUtc§1539869400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c8c1753f-e5d6-313a-977a-f2458bf9394b
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§1.0
targetMeanPrice§5.0
targetMedianPrice§5.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§2.833
grossMargins§0.87464994
ebitdaMargins§0.0
trailingPegRatio§None
